VAXiCAN

VAXiCAN, pre-clinical stage biotechnology company with vision to create Next Generation Immunotherapeutics, develops unique novel platform of therapeutic cancer vaccines based on proprietary enveloped virus-like particles (Enveloped VLPs), which provide the safest and most effective way of instructing and strengthening the Patient's anticancer defense mechanisms. VAXiCAN VLP platform is widely supported by fully owned and in-house developed novel dedicated proprietary elements of machine learning (ML) and artificial intelligence (AI). The path chosen by the VAXiCAN is the use of naturally occurring or genetically modified oncolytic viruses using an innovative antigen delivery method using insect models (most similar solutions use mammalian, fungal or completely synthetic models). VAXiCAN VLP vaccines are designed to present the extracellular domains of cancer antigens while leveraging the immune system's mechanism to mimic viral infection, thereby enhancing antigen presentation through the recognition of pathogen-associated molecular patterns (PAMPs). This strategy not only stimulates a strong adaptive immune response characterized by the production of high-affinity antibodies and cytotoxic T cells crucial for targeting tumor cells, but also actively engages natural killer cells supported by memory cells. First pre-clinical lead candidates are addressing HER2 and GD2 cancers, incl. breast cancer, neuroblastoma, melanoma as well as HPV/HBV-related cancers with potential of at least two first-in-class drug candidates and at least one in the orphan drug and fast track regulatory designations. VAXiCAN also operates in the field of modern whole viral and protein sequencing acting as Oxford Nanopore certified partner. We specialize in bioinformatic analysis of full genomes of microorganisms, including bacteria, bacteriophages, human and animal viruses as well as full human genomes.